相似文献
1
c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance.
Cell Signal. 2010 Mar;22(3):553-63. doi: 10.1016/j.cellsig.2009.11.012.
2
Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells.
J Cancer Res Clin Oncol. 2012 Aug;138(8):1279-89. doi: 10.1007/s00432-012-1204-4. Epub 2012 Mar 24.
3
c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment.
Cell Signal. 2010 Mar;22(3):377-85. doi: 10.1016/j.cellsig.2009.10.007.
4
DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells.
Mol Oncol. 2017 Dec;11(12):1733-1751. doi: 10.1002/1878-0261.12140. Epub 2017 Oct 27.
5
c-Cbl shRNA-expressing adenovirus sensitizes TRAIL-induced apoptosis in prostate cancer DU-145 through increases of DR4/5.
Cancer Gene Ther. 2013 Feb;20(2):82-7. doi: 10.1038/cgt.2012.88. Epub 2013 Jan 11.
6
Regulation in the targeting of TRAIL receptor 1 to cell surface via GODZ for TRAIL sensitivity in tumor cells.
Cell Death Differ. 2012 Jul;19(7):1196-207. doi: 10.1038/cdd.2011.209. Epub 2012 Jan 13.
7
TRAIL/MEKK4/p38/HSP27/Akt survival network is biphasically modulated by the Src/CIN85/c-Cbl complex.
Cell Signal. 2013 Jan;25(1):372-9. doi: 10.1016/j.cellsig.2012.10.010. Epub 2012 Oct 23.
8
Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL.
Exp Cell Res. 2007 Jul 1;313(11):2378-88. doi: 10.1016/j.yexcr.2007.03.018. Epub 2007 Mar 30.
9
TRAIL-activated EGFR by Cbl-b-regulated EGFR redistribution in lipid rafts antagonises TRAIL-induced apoptosis in gastric cancer cells.
Eur J Cancer. 2012 Nov;48(17):3288-99. doi: 10.1016/j.ejca.2012.03.005. Epub 2012 Mar 27.
10
DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.
Cancer Biol Ther. 2014;15(12):1658-66. doi: 10.4161/15384047.2014.972183.
引用本文的文献
1
TNF-Related Apoptosis-Inducing Ligand: Non-Apoptotic Signalling.
Cells. 2024 Mar 16;13(6):521. doi: 10.3390/cells13060521.
2
Lewis glycosphingolipids as critical determinants of TRAIL sensitivity in cancer cells.
Oncogene. 2022 Sep;41(38):4385-4396. doi: 10.1038/s41388-022-02434-3. Epub 2022 Aug 15.
3
Death Receptors DR4 and DR5 Undergo Spontaneous and Ligand-Mediated Endocytosis and Recycling Regardless of the Sensitivity of Cancer Cells to TRAIL.
Front Cell Dev Biol. 2021 Sep 30;9:733688. doi: 10.3389/fcell.2021.733688. eCollection 2021.
4
Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis.
Theranostics. 2021 Feb 15;11(8):3964-3980. doi: 10.7150/thno.54824. eCollection 2021.
5
Dexamethasone Inhibits TRAIL-Induced Apoptosis through c-FLIP(L) Upregulation and DR5 Downregulation by GSK3β Activation in Cancer Cells.
Cancers (Basel). 2020 Oct 9;12(10):2901. doi: 10.3390/cancers12102901.
6
Upregulation of DR5 and Downregulation of Survivin by IITZ-01, Lysosomotropic Autophagy Inhibitor, Potentiates TRAIL-Mediated Apoptosis in Renal Cancer Cells via Ubiquitin-Proteasome Pathway.
Cancers (Basel). 2020 Aug 21;12(9):2363. doi: 10.3390/cancers12092363.
7
Ischemic Preconditioning Upregulates Decoy Receptors to Protect SH-SY5Y Cells from OGD Induced Cellular Damage by Inhibiting TRAIL Pathway and Agitating PI3K/Akt Pathway.
Mol Neurobiol. 2020 Sep;57(9):3658-3670. doi: 10.1007/s12035-020-01978-3. Epub 2020 Jun 20.
8
Inflammatory bowel disease-associated ubiquitin ligase RNF183 promotes lysosomal degradation of DR5 and TRAIL-induced caspase activation.
Sci Rep. 2019 Dec 30;9(1):20301. doi: 10.1038/s41598-019-56748-6.
9
Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway.
Cell Death Discov. 2019 Dec 10;5:153. doi: 10.1038/s41420-019-0228-9. eCollection 2019.
10
Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells.
Cell Death Dis. 2019 Feb 11;10(2):118. doi: 10.1038/s41419-019-1383-x.
本文引用的文献
1
Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
J Biol Chem. 2007 Apr 27;282(17):12831-41. doi: 10.1074/jbc.M700438200. Epub 2007 Feb 27.
2
Evidence for two modes of development of acquired tumor necrosis factor-related apoptosis-inducing ligand resistance. Involvement of Bcl-xL.
J Biol Chem. 2007 Jan 5;282(1):319-28. doi: 10.1074/jbc.M608065200. Epub 2006 Nov 15.
3
Inhibition of TNF receptor 1 internalization by adenovirus 14.7K as a novel immune escape mechanism.
J Clin Invest. 2006 Nov;116(11):2901-13. doi: 10.1172/JCI23771. Epub 2006 Oct 5.
4
The role of receptor internalization in CD95 signaling.
EMBO J. 2006 Mar 8;25(5):1009-23. doi: 10.1038/sj.emboj.7601016. Epub 2006 Feb 23.
5
Ubiquitylation of leptin receptor OB-Ra regulates its clathrin-mediated endocytosis.
EMBO J. 2006 Mar 8;25(5):932-42. doi: 10.1038/sj.emboj.7600989. Epub 2006 Feb 16.
6
Structural characterization of a novel Cbl phosphotyrosine recognition motif in the APS family of adapter proteins.
J Biol Chem. 2005 May 13;280(19):18943-9. doi: 10.1074/jbc.M414157200. Epub 2005 Feb 28.
7
Recognition of the tryptophan-based endocytosis signal in the neonatal Fc Receptor by the mu subunit of adaptor protein-2.
J Biol Chem. 2005 Feb 25;280(8):7309-16. doi: 10.1074/jbc.M410752200. Epub 2004 Dec 14.
8
Targeting death receptors in cancer with Apo2L/TRAIL.
Curr Opin Pharmacol. 2004 Aug;4(4):333-9. doi: 10.1016/j.coph.2004.02.006.
9
c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes.
J Biol Chem. 2004 Aug 27;279(35):37153-62. doi: 10.1074/jbc.M403210200. Epub 2004 Jun 21.
10
Overcoming acquired resistance to TRAIL by chemotherapeutic agents and calpain inhibitor I through distinct mechanisms.
Mol Ther. 2004 May;9(5):666-73. doi: 10.1016/j.ymthe.2004.02.007.
Zotero 插件